TikkunLev Therapeutics brings together diverse talents with deep roots in biotechnology therapeutic development, gene therapy R&D, cardiology, and heart failure.
Deep operational, strategic, and R&D experience in cardiology and precision and gene therapy development. Founding Head of Cardiovascular Research at BioMarin and former CSO at Renovacor. Led portfolio and commercial-strategy-initiatives at BioMarin and Biogen.
Director of the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), and Presidential Endowed Chair and Professor of Medicine. Serial innovator in cardiovascular disease, discovering novel drug targets and gene therapies.
25 years experience in gene therapy and biologics R&D. Former Gene Therapy group leader and product reviewer at the FDA’s Division of Cell and Gene Therapy
35 years in the pharmaceutical and medical device R&D and commercialization. Led Business Development for Clinical Diagnostics at Janssen and former commercial leader at Novartis
Over 20 years of experience as an executive, investor and advisor within the life sciences industry across several therapeutic areas with a recent focus on rare diseases and gene therapy. Recently served as the chief executive officer of Renovacor, a rare disease CV gene therapy company, acquired by Rocket Pharma.